Early Viral Kinetics in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals

This is the authors' abstract. We don't add key points for this paper.

Objectives:We aimed to determine parameters affecting viral kinetics among the first case series of chronic hepatitis C treated with direct-acting oral antiviral drugs in a tertiary university hospital and thus contribute to real-life data on direct-acting antiviral (DAA) treatments.Materials and Methods: This is a prospective observational study that enrolled patients with chronic hepatitis C infection who were followed up between 2017 and 2019 and administered DAA treatment.Hepatitis C virus (HCV)-RNA (real-time polymerase chain reaction) was detected in the plasma samples of the patients before treatment (day 0) and on the 3 rd and 7 th days of treatment.Test results below 35 IU/mL were considered negative. Results:The paritaprevir/ritonavir/ombitasvir/dasabuvir regimen was administered to 21 (44%) patients, sofosbuvir-based regimens to 28 (54%) patients, and glecaprevir-pibrentasvir treatment to 1 (2%) patient.HCV-RNA was detected to be negative significantly earlier in younger patients (p=0.005).The median disease duration was 7 years (range: 2-10), and viral clearance was obtained significantly earlier (p=0.038) in patients with a longer disease duration.The median initial viral load was 3,079,870 Z Ama: nc basamak bir niversite hastanesinde direkt etkili oral antiviral ilalarla tedavi edilen kronik hepatit C'li ilk olgu serilerinde viral kinetikleri etkileyen parametreleri belirleyerek direkt etkili antiviral (DAA) tedavilere ilikin gerek yaam verilerine katkda bulunmay amaladk.Gere ve Yntemler: Bu alma prospektif gzlemsel nitelikte olup, 2017-2019 yllar arasnda takip edilen, kronik hepatit C tanl, DAA tedavi balanmas planlanan gnll hastalar ardk ekilde dahil edildi.Tedavinin 0. 3. ve 7. gnlerinde plazmada hepatit C virs (HCV)-RNA alld.Gerek zamanl-polimeraz zincir reaksiyonu platformu olarak COBAS TaqMan HCV test (versiyon 2.0, Roche Molecular Systems, ABD) kullanld.Bulgular: almaya alnan 50 hastadan 28'i (%56) kadn, ya ortalamas 5812,84 idi.Hastalardan 21'ine (%44) paritaprevirritonavir-ombitasvir-dasabuvir, 28'ine (%54) ise sofosbuvir ieren ilalar, 1'ine (%2) glecaprevir-pibrentasvir tedavisi verildi.Ya daha gen olanlarda (p=0,005) ve hastalk sresi daha uzun olanlarda (p=0,038) viral klirensin daha erken saland saptand.Balang viral yk ortancas 3.079.870IU/mL idi, viral klirensin salanma